Indo Us Biotech Limited — Results, 12-08-2025: Integrated Filing- Financial

Indo US Bio-Tech's standalone revenue for the quarter ended June 30, 2025, surged to `47.50 Cr`, marking a strong 32.83% increase year-over-year. The company operates solely in the `Agricultural Seeds` segment, which drove this growth.

Profitability saw a significant turnaround, with net profit at `0.48 Cr` for the quarter, compared to a `loss of 0.01 Cr` in the same period last year. Earnings Per Share (EPS) stood at `0.18`, a positive shift from the previous year's negative EPS.

Total expenses rose to `46.85 Cr` from `35.78 Cr` YoY, largely in line with revenue growth. Cost of materials consumed increased to `38.37 Cr` from `28.00 Cr`. While employee benefits and other expenses also increased, overall efficiency appears maintained given the substantial profit turnaround.

The quarter shows positive momentum with robust revenue growth and a return to profitability, indicating a stable outlook for the company in its `Agricultural Seeds` business.